Drug intelligence / Profile preview

MNT104

Development stage: Preclinical
Lead developer: Magnaetus Therapeutics
Modality: Peptides

Overview

MNT104 is a peptide-based replacement therapy under development by Magnaetus Therapeutics for the treatment of obesity and metabolic syndrome. The drug is designed to restore physiological levels of a specific metabolic peptide, aiming to address the underlying hormonal imbalances associated with weight gain and metabolic dysfunction. As of 2024, the program is in the early stages of development, focusing on metabolic health and weight management.

Targets

mTOR (Mammalian target of rapamycin kinase)

Beyond the preview

Go deeper on MNT104.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MNT104.

Explore the full profile